N-(2,4-difluorophenylmethyl)-N-t-butylamine | 204707-22-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(2,4-difluorophenylmethyl)-N-t-butylamine
• 英文别名: N-[(2,4-difluorophenyl)methyl]-2-methylpropan-2-amine
• CAS: 204707-22-2
• 化学式: C₁₁H₁₅F₂N
• 分子量: 199.244
• InChiKey: AJIPIVAIKLIBDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  N-(2,4-difluorobenzylidene)-t-butylamine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 以83%的产率得到N-(2,4-difluorophenylmethyl)-N-t-butylamine
  参考文献：
  名称：

  Nitrone derivatives

  摘要：

  化合物如图（1）所示或其药学上可接受的盐，可用作治疗视网膜退行性疾病的药物：其中，Ar是可选取代的苯基或可选取代的杂环基；n为0、1或2；W为—CH2NH—或—CH═N(O)—；R1、R2和R3各自独立地是可选取代的烷基、羧基或烷氧羰基；R1、R2和R3中的任意两个基团可与碳原子一起形成可选取代的环烷烃；R1、R2和R3中的所有基团可与相邻的碳原子一起形成可选取代的双环烷烃或可选取代的三环烷烃；R4和R5各自独立地是氢原子或可选取代的烷基。

  公开号：

  US06194461B1

文献信息

• P38 kinase inhibiting agents
  申请人：Chen Meng-Hsin

  公开号：US20070129372A1

  公开（公告）日：2007-06-07

  Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

  化学式（I）描述的化合物或其药用盐：是p38的抑制剂，可用于治疗炎症，如治疗类风湿关节炎、类风湿脊柱炎、骨关节炎、痛风性关节炎和其他关节炎症状；发炎关节、湿疹、牛皮癣或其他炎症性皮肤病症，如晒伤；包括结膜炎在内的炎症性眼部疾病；发热、疼痛和其他与炎症相关的病症。
• Novel Lipopeptides as Antibacterial Agents
  申请人：Hill Jason

  公开号：US20090011977A1

  公开（公告）日：2009-01-08

  The present invention relates to novel lipopeptide compounds. The invention also relates to pharmaceutical compositions of these compounds and methods of using these compounds as antibacterial compounds. The invention also relates to methods of producing these novel lipopeptide compounds and intermediates used in producing these compounds.

  本发明涉及新型脂肽化合物。本发明还涉及这些化合物的药物组合物以及将这些化合物用作抗菌化合物的方法。本发明还涉及生产这些新型脂肽化合物的方法以及用于生产这些化合物的中间体。
• P38 Kinase Inhibiting Agents
  申请人：Chen Meng-Hsin

  公开号：US20090088436A1

  公开（公告）日：2009-04-02

  Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.

  化学式(I)或其药学上可接受的盐所描述的化合物：是p38的抑制剂，可用于治疗炎症，如类风湿性关节炎、类风湿性脊柱炎、骨关节炎、痛风性关节炎和其他关节炎症状；发炎的关节、湿疹、牛皮癣或其他炎症性皮肤病，如晒伤；炎症性眼部疾病，包括结膜炎；与炎症相关的发热、疼痛和其他症状。
• NITRONE DERIVATIVES
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0945426A1

  公开（公告）日：1999-09-29

  A compound represented by the figure (1) or a pharmaceutically acceptable salt thereof is useful as a medicament for treating retinal degenerative disorders: wherein Ar is optionally substituted phenyl or optionally substituted heteroaryl;. n is 0, 1 or 2; W is -CH2NH- or -CH=N(O)-; R1, R2 and R3 are independently optionally substituted alkyl, carboxyl or alkoxycarbonyl; any two groups of R1, R2 and R3 may be taken together with the carbon atom to form optionally substituted cycloalkane; all of R1, R2 and R3 may be taken together with the adjusent carbon atom to form optionally substituted bicycloalkane or optionally substituted tricycloalkane; R4 and R5 are independently hydrogen atom or optionally substituted alkyl.

  图（1）所代表的化合物或其药学上可接受的盐可作为治疗视网膜变性疾病的药物： 其中 Ar 是任选取代的苯基或任选取代的杂芳基；. n 是 0、1 或 2； W是-CH2NH-或-CH=N(O)-； R1、R2 和 R3 独立地是任选取代的烷基、羧基或烷氧基羰基；R1、R2 和 R3 中的任意两个基团可与碳原子结合形成任选取代的环烷；所有 R1、R2 和 R3 可与相邻碳原子结合形成任选取代的双环烷或任选取代的三环烷； R4 和 R5 独立地为氢原子或任选取代的烷基。
• PIPERIDINE-DIONE DERIVATIVES
  申请人：Genentech, Inc.

  公开号：US20170001990A1

  公开（公告）日：2017-01-05

  The invention provides novel compounds having the general formula: and tautomers and pharmaceutically acceptable salts thereof, wherein A 1 , A 2 , A 3 , A 4 , R 1 , R 4 , R 5 , R 6 , R 7 and R 8 are as defined herein, compositions including the compounds and methods of using the compounds.